Amylyx Pharmaceuticals (AMLX) Work In Process (2022)
Amylyx Pharmaceuticals (AMLX) posted Work In Process of $1.7 million for Q4 2022, up 3635.56% on a QoQ basis from $45000.0 in Q3 2022.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Work In Process (2022) Analysis & Trends
Amylyx Pharmaceuticals has reported Work In Process for 1 years, with the latest figure at $1.7 million in Q4 2022.
- On a quarterly basis, Work In Process changed N/A year-over-year to $1.7 million in Q4 2022; TTM through Dec 2022 was $1.7 million, a N/A change from a year earlier, with the FY2022 full-year figure at $1.7 million, changed N/A from the prior year.
- Work In Process was $1.7 million for Q4 2022 at Amylyx Pharmaceuticals, up from $45000.0 in the prior quarter.
- The five-year high for Work In Process was $1.7 million in Q4 2022, with the low at $45000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn |
| 10 | Amylyx Pharmaceuticals | 3.68 Bn | 3.68 Bn | - |